Radiation and new molecular agents, part II: Targeting HDAC, HSP90, IGF-1R, PI3K, and Ras

Seminars in Radiation Oncology

Volumn 16, Issue 1, 2006, Pages 59-64

  Chinnaiyan, Prakash ^a   Allen, Gregory W ^a   Harari, Paul M ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; AP 23573; ARYLBUTYRIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; BUTYRIC ACID; CETUXIMAB; DEPSIPEPTIDE; EVEROLIMUS; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; L 778123; LONAFARNIB; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; SHORT CHAIN FATTY ACID; SOMATOMEDIN C RECEPTOR; TEMSIROLIMUS; TETRAPEPTIDE; TIPIFARNIB; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

BILE DUCT CARCINOMA; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFICACY; HEAD AND NECK CANCER; HUMAN; LUNG SMALL CELL CANCER; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN TARGETING; RADIATION RESPONSE; REVIEW; TUMOR GROWTH;

EID: 29244492286     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2005.08.008     Document Type: Article

References (55)

1. J.A. Bonner, M.J. Giralt, P.M. Harari Cetuximab prolongs survival in patients with locregionally advanced squamous cell carcinoma of head and neck A phase III study of high dose radiation therapy with or without cetuximab J Clin Oncol 22 Supl 2004 5507
2. P. Marks, R.A. Rifkind, V.M. Richon Histone deacetylases and cancer Causes and therapies Nat Rev Cancer 1 2001 194 202
3. R.W. Johnstone Histone-deacetylase inhibitors Novel drugs for the treatment of cancer Nat Rev Drug Discov 1 2002 287 299
4. M. Ljungman The influence of chromatin structure on the frequency of radiation-induced DNA strand breaks A study using nuclear and nucleoid monolayers Radiat Res 126 1991 58 64
5. R.L. Warters, T.J. Childers Radiation-induced thymine base damage in replicating chromatin Radiat Res 90 1982 564 574
6. K. Camphausen, T. Scott, M. Sproull Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation Clin Cancer Res 10 2004 6066 6071
7. P. Chinnaiyan, G. Valabhaneni, E. Armstrong Modulating radiation response with the histone deacetylase (HDAC) inhibitor SAHA in human carcinomas Int J Radiat Oncol Biol Phys 62 2005 223 229
8. L. Fuino, P. Bali, S. Wittmann Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B Mol Cancer Ther 2 2003 971 984
9. X. Yu, Z.S. Guo, M.G. Marcu Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228 J Natl Cancer Inst 94 2002 504 513
10. M.E. Lippman, C. Benz, A. Chinnaiyan Consensus statement Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer - The Development and Validation of New Therapeutics ' Breast Cancer Res Treat 90 2005 1 3
11. K. Camphausen, W. Burgan, M. Cerra Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275 Cancer Res 64 2004 316 321
12. E.P. Rogakou, D.R. Pilch, A.H. Orr DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139 J Biol Chem 273 1998 5858 5868
13. K. Rothkamm, I. Kruger, L.H. Thompson Pathways of DNA double-strand break repair during the mammalian cell cycle Mol Cell Biol 23 2003 5706 5715
14. A. Maloney, P. Workman HSP90 as a new therapeutic target for cancer therapy The story unfolds Expert Opin Biol Ther 2 2002 3 24
15. J.S. Russell, W. Burgan, K.A. Oswald Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin A multitarget approach to radiosensitization Clin Cancer Res 9 2003 3749 3755
16. K.S. Bisht, C.M. Bradbury, D. Mattson Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity Cancer Res 63 2003 8984 8995
17. R. Enmon, W.H. Yang, A.M. Ballangrud Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids Cancer Res 63 2003 8393 8399
18. A. Zhu, J. Shaeffer, S. Leslie Epidermal growth factor receptor an independent predictor of survival in astrocytic tumors given definitive irradiation Int J Radiat Oncol Biol Phys 34 1996 809 815
19. M.T. Sheridan, T. O'Dwyer, C.B. Seymour Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck Radiat Oncol Investig 5 1997 180 186
20. L. Milas, Z. Fan, N.H. Andratschke Epidermal growth factor receptor and tumor response to radiation In vivo preclinical studies Int J Radiat Oncol Biol Phys 58 2004 966 971
21. S.M. Huang, J.M. Bock, P.M. Harari Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck Cancer Res 59 1999 1935 1940
22. D.B. Agus, H.I. Scher, B. Higgins Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models Cancer Res 59 1999 4761 4764
23. T.M. Grana, E.V. Rusyn, H. Zhou Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways Cancer Res 62 2002 4142 4150
24. S.G. Kennedy, A.J. Wagner, S.D. Conzen The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal Genes Dev 11 1997 701 713
25. W.G. McKenna, R.J. Muschel, A.K. Gupta The RAS signal transduction pathway and its role in radiation sensitivity Oncogene 22 2003 5866 5875
26. M.N. Pollak, E.S. Schernhammer, S.E. Hankinson Insulin-like growth factors and neoplasia Nat Rev Cancer 4 2004 505 518
27. C. Bahr, B. Groner The insulin like growth factor-1 receptor (IGF-1R) as a drug target Novel approaches to cancer therapy Growth Horm IGF Res 14 2004 287 295
28. R. Baserga, F. Peruzzi, K. Reiss The IGF-1 receptor in cancer biology Int J Cancer 107 2003 873 877
29. S.E. Dunn, R.A. Hardman, F.W. Kari Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs Cancer Res 57 1997 2687 2693
30. B.C. Turner, B.G. Haffty, L. Narayanan Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation Cancer Res 57 1997 3079 3083
31. C. Garcia-Echeverria, M.A. Pearson, A. Marti In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase Cancer Cell 5 2004 231 239
32. D. Burtrum, Z. Zhu, D. Lu A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo Cancer Res 63 2003 8912 8921
33. B.D. Cohen, D.A. Baker, C. Soderstrom Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871 Clin Cancer Res 11 2005 2063 2073
34. G.A. Allen, E. Armstrong, F. Modhia Inhibition of insulin-like growth factor-1 receptor signaling impairs proliferation of head and neck, lung, prostate and breast cancer cells Proc AACR 2005 5041 (abstr)
35. S. Nakamura, H. Watanabe, M. Miura Effect of the insulin-like growth factor I receptor on ionizing radiation-induced cell death in mouse embryo fibroblasts Exp Cell Res 235 1997 287 294
36. E.S. Perer, A.K. Madan, A. Shurin Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells J Surg Res 94 2000 1 5
37. V.M. Macaulay, A.J. Salisbury, E.A. Bohula Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase Oncogene 20 2001 4029 4040
38. B. Wen, E. Deutsch, E. Marangoni Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells Br J Cancer 85 2001 2017 2021
39. Y. Min, Y. Adachi, H. Yamamoto Genetic blockade of the insulin-like growth factor-I receptor A promising strategy for human pancreatic cancer Cancer Res 63 2003 6432 6441
40. Y. Adachi, C.T. Lee, D.P. Carbone Genetic blockade of the insulin-like growth factor 1 receptor for human malignancy Novartis Found Symp 262 2004 177 189 discussion 190-192, 265-268
41. M.A. Rochester, J. Riedemann, G.O. Hellawell Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer Cancer Gene Ther 12 2005 90 100
42. O. Riesterer, A. Tenzer, D. Zingg Novel radiosensitizers for locally advanced epithelial tumors inhibition of the PI3K/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy? Int J Radiat Oncol Biol Phys 58 2004 361 368
43. K. Soderlund, G. Perez-Tenorio, O. Stal Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells Int J Oncol 26 2005 25 32
44. J.L. Nakamura, A. Karlsson, N.D. Arvold PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas J Neurooncol 71 2005 215 222
45. S. Tanno, N. Yanagawa, A. Habiro Serine/threonine kinase AKT is frequently activated in human bile duct cancer and is associated with increased radioresistance Cancer Res 64 2004 3486 3490
46. A.K. Gupta, G.J. Cerniglia, R. Mick Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002 Int J Radiat Oncol Biol Phys 56 2003 846 853
47. F. Meric-Bernstam, G.B. Mills Mammalian target of rapamycin Semin Oncol 31 suppl 16 2004 10 17 discussion 33
48. J. Li, C. Yen, D. Liaw PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 275 1997 1943 1947
49. J.S. Eshleman, B.L. Carlson, A.C. Mladek Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy Cancer Res 62 2002 7291 7297
50. S.M. Hahn, E. Bernhard, W.G. McKenna Farnesyltransferase inhibitors Semin Oncol 28 suppl 16 2001 86 93
51. H.A. Jones, S.M. Hahn, E. Bernhard Ras inhibitors and radiation therapy Semin Radiat Oncol 11 2001 328 337
52. Y. Shi, J. Wu, R. Mick Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival Prostate 62 2005 69 82
53. R.A. Alcock, S. Dey, D. Chendil Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2 Oncogene 21 2002 7883 7890
54. T.B. Brunner, A.K. Gupta, Y. Shi Farnesyltransferase inhibitors as radiation sensitizers Int J Radiat Biol 79 2003 569 576
55. C. Delmas, C. Heliez, E. Cohen-Jonathan Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation Int J Cancer 100 2002 43 48